One To Watch

Serum Institute of India

A Pune-based immunobiologicals pioneer that has grown into the world's largest vaccine manufacturer by dose volume, supplying prophylactic and combination vaccines to over 170 countries.

Company Overview

A Pune-based immunobiologicals pioneer that has grown into the world's largest vaccine manufacturer by dose volume, supplying prophylactic and combination vaccines to over 170 countries. Founded to reduce India's dependence on expensive imported biologicals, Serum Institute of India (SII) now produces more than 1.5 billion doses annually across its vaccine portfolio. The company has expanded beyond its domestic mandate into global health security, epidemic preparedness, and monoclonal antibody development. SII is a privately held entity within the Poonawalla Group and operates manufacturing infrastructure across India and the Netherlands.

Headquarters and Global Presence

SII is headquartered in Pune, Maharashtra, India, with its principal manufacturing campuses located in the city. Its 2012 acquisition of Bilthoven Biologicals (BBIO) extended its European footprint into the Netherlands, providing capabilities in monoclonal antibody production and inactivated vaccine manufacturing. The company distributes products across low- and middle-income countries (LMICs), with strategic supply relationships coordinated through Gavi and CEPI.

Founding and History

SII was founded in 1966 by Dr. Cyrus Poonawalla with a mandate to manufacture life-saving immunobiologicals domestically, replacing high-cost imports. Early products included tetanus antitoxin, snake antivenom, DPT, and MMR vaccines. The company made its first international acquisition in June 2012, purchasing Bilthoven Biologicals from the Dutch government. SII's profile rose sharply during the COVID-19 pandemic, when it manufactured the AstraZeneca-Oxford vaccine (Covishield) and Novavax's Covovax at scale for global distribution.

Therapy Areas and Focus

SII's primary focus is infectious disease prevention, spanning bacterial, viral, and parasitic pathogens. Its portfolio addresses diseases of high global burden including poliomyelitis, meningitis, pneumonia, cervical cancer, dengue, malaria, and Rift Valley fever. The company is increasingly active in diseases prevalent in LMICs, where its cost structure and manufacturing scale offer a competitive advantage. An emerging monoclonal antibody program, developed in partnership with IAVI and DNDi, broadens SII's scope into HIV and dengue treatment.

Technology Platforms and Modalities

SII deploys multiple vaccine modalities including prophylactic vaccines, conjugated vaccines, combination vaccines, and live attenuated vaccines. Its Bilthoven subsidiary adds monoclonal antibody manufacturing capability to this platform mix. The company has licensed Genticel's Vaxiclase technology for use in acellular multivalent combination vaccines incorporating pertussis antigens. A growing portfolio of next-generation candidates incorporates adjuvant systems and multi-antigen approaches, exemplified by the R21/Matrix-M malaria vaccine developed with Oxford and Novavax.

Key Pipeline and Programs

The R21/Matrix-M malaria vaccine, developed in partnership with the University of Oxford and using Novavax's Matrix-M adjuvant, has received regulatory approval in several African countries and represents SII's most advanced novel product. Oxford and SII have also entered a licensing agreement, supported by CEPI, for R78C — a next-generation multi-stage malaria vaccine candidate that combines the R21 pre-erythrocytic component with the RH5.1 blood-stage antigen, aiming for broader protection. A quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer completed Phase II/III clinical trials, and SII has sought Indian regulatory approval for domestic manufacturing and deployment. On the infectious disease front, SII is scaling inactivated poliomyelitis vaccine (IPV) supply to meet India's full annual demand following Sanofi's withdrawal, while its dengue monoclonal antibody program is advancing in clinical development in Brazil and Southeast Asia in collaboration with DNDi. Covovax (NVX-CoV2373), manufactured under the Novavax partnership, has received emergency use authorization in multiple markets including for adolescents aged 12 to 18 years.

Recent Developments

In February 2026, SII signed a licensing agreement with the University of Oxford for the investigational Rift Valley fever vaccine, with CEPI support, creating the largest-ever reserve of the candidate ahead of testing — timed to an active outbreak in Senegal and Mauritania. In April 2026, Colombian biotech VaxThera entered a strategic collaboration with SII to strengthen vaccine manufacturing and health security in Colombia. In mid-2024, SII joined CEPI's global network of vaccine producers in the Global South and announced plans to significantly expand HPV vaccine supply for government immunization campaigns at reduced pricing. Also in 2024, SII formalized a partnership with IAVI to develop affordable monoclonal antibody products targeting HIV and other global health challenges.

Key Personnel

Adar Poonawalla serves as Chief Executive Officer. The son of founder Dr. Cyrus Poonawalla, he has led SII's transformation into a global vaccine supplier and was a central figure in its pandemic-era manufacturing scale-up. Dr. Prasad Kulkarni serves as Executive Director and has been the public face of SII's partnership strategy, including the DNDi dengue monoclonal antibody collaboration. Soumitro Bhattacharyya and Parag Deshmukh round out the senior executive team in operational and financial leadership roles.

Strategic Partnerships

SII's partnership portfolio spans pandemic preparedness, tropical disease, and global health equity. Key relationships include Novavax (Covovax manufacturing and antigen supply), the University of Oxford and CEPI (R21/Matrix-M malaria vaccine and R78C next-generation candidate, and Rift Valley fever vaccine), IAVI (monoclonal antibodies for HIV), DNDi (dengue monoclonal antibody clinical development in Brazil and Southeast Asia), and Gavi and the Bill and Melinda Gates Foundation (COVID-19 vaccine supply to LMICs). Panacea Biotec holds long-term collaboration agreements with both SII and its Bilthoven subsidiary.

FAQ Section

SII claims the title of world's largest vaccine manufacturer by dose volume, producing over 1.5 billion doses annually. Its cost structure and scale allow it to serve as a primary supplier to Gavi-backed immunization programs across LMICs. Membership in CEPI's Global South network further cements its role in epidemic preparedness and surge manufacturing capacity.

R78C combines two distinct mechanisms of protection: the R21 pre-erythrocytic antigen, which prevents the parasite from infecting liver cells, and the RH5.1 blood-stage antigen, which neutralizes the parasite after liver-stage breakthrough. This two-pronged approach could deliver materially higher and more durable efficacy than single-stage vaccines. The Oxford-SII licensing deal for R78C is supported by CEPI, reflecting recognition of its public health potential.

SII combines extreme manufacturing scale with a deliberately low-cost pricing model designed for LMIC affordability — a combination rare among vaccine producers of its size. Its vertically integrated operations in Pune, augmented by the Dutch Bilthoven Biologicals subsidiary for monoclonal antibody and inactivated vaccine capability, give it unusual platform breadth. Strategic autonomy as a private, family-controlled company allows it to commit to long-term global health partnerships without short-term shareholder pressure.

SII's indigenously developed quadrivalent human papillomavirus (qHPV) vaccine completed Phase II/III clinical trials and the company has applied to India's drug regulator for manufacturing approval. The aim is to supply the vaccine at reduced government rates to support a national immunization campaign targeting cervical cancer prevention. If approved, SII's production scale could substantially lower the per-dose cost compared with existing imported HPV vaccines.

While vaccines remain the core, SII is building a monoclonal antibody capability spanning HIV prevention (with IAVI) and dengue treatment (with DNDi, in clinical development in Brazil and Southeast Asia). The Bilthoven Biologicals subsidiary provides dedicated MAb manufacturing infrastructure. This expansion reflects a strategic intent to capture the growing biologics access gap in LMICs beyond the traditional vaccine category.

SII's most advanced novel asset — the R21/Matrix-M malaria vaccine — has already received regulatory approval in multiple African markets and is in commercial rollout. The qHPV cervical cancer vaccine is at the regulatory submission stage following completed Phase II/III trials. The R78C multi-stage malaria candidate and the Rift Valley fever vaccine are earlier-stage, with SII focused on building reserve stockpiles and advancing toward human trials under CEPI's epidemic preparedness framework.

Key watchpoints for SII include:

Regulatory decision on the qHPV vaccine in India, which would open a large government procurement contract
Clinical progression of R78C and efficacy data relative to R21 alone, which would validate the multi-stage strategy
Scale-up of IPV supply to replace Sanofi, a significant volume opportunity in India's national immunization program
Advancement of the DNDi dengue monoclonal antibody through clinical trials in Brazil and Southeast Asia
Execution risk in the Rift Valley fever vaccine reserve program under CEPI, where outbreak dynamics could accelerate or delay timelines
Geopolitical and regulatory risk inherent in operating a global LMIC-focused supply chain dependent on multilateral funding from Gavi, CEPI, and the Gates Foundation

Want to Update your Company's Profile?